middle.news

PYC Therapeutics Advances PKD Drug with Phase 1b Trial

9:26am on Thursday 7th of May, 2026 AEST Biotechnology
Read Story

PYC Therapeutics Advances PKD Drug with Phase 1b Trial

9:26am on Thursday 7th of May, 2026 AEST
Key Points
  • Phase 1b Multiple Ascending Dose trial initiated
  • First PKD patient dosed with PYC-003
  • Study to assess safety, tolerability, and biomarkers
  • Phase 1a data expected in second half 2026
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about PYC Therapeutics (ASX:PYC)
OPEN ARTICLE